$0.31
-0.02 (-5.86%)
Open$0.33
Previous Close$0.33
Day High$0.34
Day Low$0.31
52W High$2.88
52W Low$0.29
Volume—
Avg Volume2.01M
Market Cap10.26M
P/E Ratio—
EPS$-1.76
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+945.2% upside
Current
$0.31
$0.31
Target
$3.24
$3.24
$1.82
$3.24 avg
$4.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 30.3K | 175.9K | 15.18M |
| Net Income | -82,915,556 | -432,602,900 | 1.21M |
| Profit Margin | -279,263.6% | -265,300.5% | 8.0% |
| EBITDA | -89,132,857 | -490,876,603 | 1.98M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | -82.8% | -82.8% | +1.7% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |